{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:57:41Z","timestamp":1776495461007,"version":"3.51.2"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":2358,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,13]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Multiple subcutaneous immunoglobulin (SCIG) products are available to treat primary antibody deficiency (PAD). The efficacy and tolerability of 16% SCIG (Vivaglobin\u00ae) was compared with 20% SCIG (Hizentra\u00ae) in PAD subjects. The study was a prospective, single-centre, open-label study of PAD subjects transitioning Vivaglobin to equivalent Hizentra doses, rounded to the nearest vial size. Comparisons included immunoglobulin (Ig)G levels; tetanus, varicella and Streptococcus pneumoniae titres; adverse events (AEs), annual infection rate and quality of life during 8 weeks of Vivaglobin and 24 weeks of Hizentra. Thirty-two subjects (aged 2\u201375\u00a0years) participated. Rounding to the nearest Hizentra vial size resulted in a 12\u00b78% (\u00b1\u00a02\u00b79%) increase in SCIG dose. Median immunoglobulin (Ig)G level following 8 weeks of Vivaglobin was similar to 24 weeks of Hizentra (1050 versus 1035\u00a0mg\/dl, respectively; P\u00a0=\u00a00\u00b777). Both products had similar protective titres to tetanus, varicella and serotypes of S. pneumoniae, which were variable but well above protective levels. After 12 weeks of Hizentra, subjects reported fewer local site reactions compared with Vivaglobin. Switching products resulted in increased systemic AEs in some subjects but, overall, not significantly higher than during Vivaglobin treatment. Average infusion time decreased from 104\u00b77\u00a0min (3\u00b73 sites) with Vivaglobin to 70\u00b77\u00a0min (2\u00b72 sites) with Hizentra (P\u00a0=\u00a00\u00b70005). Acute serious bacterial infections were similar. Treatment satisfaction was superior with Hizentra. Hizentra and Vivaglobin have similar pharmacokinetics and efficacy. Although transition to a different SCIG product initially increased AEs, Hizentra is well tolerated and can be infused more rapidly and with fewer sites compared to Vivaglobin.<\/jats:p>","DOI":"10.1111\/cei.12623","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T03:59:06Z","timestamp":1426132746000},"page":"441-450","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency"],"prefix":"10.1093","volume":"181","author":[{"given":"H B","family":"Niebur","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Duff","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G F","family":"Shear","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T K","family":"Alberdi","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Dorsey","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J W","family":"Sleasman","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"2021122010153390000_cei12623-bib-0001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"94","author":"Bonilla","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021122010153390000_cei12623-bib-0002","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0003","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021122010153390000_cei12623-bib-0004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","article-title":"Subcutaneous immunoglobulin replacement in primary immunodeficiencies","volume":"112","author":"Berger","year":"2004","journal-title":"Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0006","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2011.04376.x","article-title":"Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies","volume":"164","author":"Borte","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"2021122010153390000_cei12623-bib-0007","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","article-title":"Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy","volume":"126","author":"Gardulf","year":"2008","journal-title":"Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med J"},{"key":"2021122010153390000_cei12623-bib-0011","first-page":"1","article-title":"Hizentra immune globulin subcutaneous (human), 20% liquid","volume":"35","author":"Anderson","year":"2010","journal-title":"P&T Product Profiler"},{"key":"2021122010153390000_cei12623-bib-0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0013","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s10875-010-9423-4","article-title":"Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency","volume":"30","author":"Hagan","year":"2010","journal-title":"J Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0014","first-page":"1","article-title":"Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies expert committee for primary immunodeficiency","volume":"5","author":"Al-Herz","year":"2014","journal-title":"Front Immunol"},{"key":"2021122010153390000_cei12623-bib-0015","volume-title":"Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency","author":"US Department of Health and Human Services, Food and Drug Administration","year":"2008"},{"key":"2021122010153390000_cei12623-bib-0016","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","article-title":"Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers","volume":"8","author":"Atkinson","year":"2005","journal-title":"Value Health"},{"key":"2021122010153390000_cei12623-bib-0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/JCP.0b013e3182401e09","article-title":"Satisfaction with methadone as a medication: psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication","volume":"32","author":"Trujols","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"2021122010153390000_cei12623-bib-0018","first-page":"291","volume-title":"The pink book: course textbook","author":"Tetanus Epidemiology and Prevention of Vaccine-Preventable Diseases","year":"2012","edition":"12th"},{"key":"2021122010153390000_cei12623-bib-0019","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR"},{"key":"2021122010153390000_cei12623-bib-0020","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"2021122010153390000_cei12623-bib-0021","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1081-1206(10)60197-4","article-title":"Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century","volume":"101","author":"Moore","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021122010153390000_cei12623-bib-0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2021122010153390000_cei12623-bib-0023","first-page":"31","volume":"49","author":"Subcutaneous immune globulin (SCIG)","year":"2007","journal-title":"Med Lett Drugs Ther"},{"key":"2021122010153390000_cei12623-bib-0024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF01541341","article-title":"Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency","volume":"14","author":"Waniewski","year":"1994","journal-title":"J Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10875-013-9876-3","article-title":"Bioavailability of IgG administered by the subcutaneous route","volume":"33","author":"Berger","year":"2013","journal-title":"J Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0026","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"2021122010153390000_cei12623-bib-0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0028","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/infdis\/148.3.472","article-title":"Enzyme-linked immunosorbent assay for susceptibility to varicella","volume":"148","author":"Shehab","year":"1983","journal-title":"J Infect Dis"},{"key":"2021122010153390000_cei12623-bib-0029","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/adc.82.2.141","article-title":"Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group","volume":"82","author":"Webb","year":"2000","journal-title":"Arch Dis Child"},{"key":"2021122010153390000_cei12623-bib-0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2006.09.036","article-title":"Validation of current joint American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children","volume":"118","author":"Kamchaisatian","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0031","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1081-1206(10)60572-8","article-title":"Assessment and clinical interpretation of polysaccharide antibody responses","volume":"99","author":"Paris","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021122010153390000_cei12623-bib-0032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/649839","article-title":"Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults","volume":"201","author":"Musher","year":"2010","journal-title":"J Infect Dis"},{"key":"2021122010153390000_cei12623-bib-0033","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biologicals.2010.11.004","article-title":"Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration","volume":"39","author":"Maeder","year":"2011","journal-title":"Biologicals"},{"key":"2021122010153390000_cei12623-bib-0034","first-page":"2","article-title":"Immune Globulin Subcutaneous (Human) Vivaglobin: for the treatment of primary immunodeficiency diseases","volume":"34","year":"2009","journal-title":"P&T Product Profiler"},{"key":"2021122010153390000_cei12623-bib-0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biologicals.2009.09.002","article-title":"L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions","volume":"38","author":"Bolli","year":"2010","journal-title":"Biologicals"},{"key":"2021122010153390000_cei12623-bib-0036","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021122010153390000_cei12623-bib-0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","article-title":"Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies","volume":"29","author":"Stein","year":"2009","journal-title":"J Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0038","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: adverse reactions and management","volume":"122","author":"Bonilla","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0039","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.yebeh.2011.04.011","article-title":"Self-reported medication adherence and treatment satisfaction in patients with epilepsy","volume":"21","author":"Sweileh","year":"2011","journal-title":"Epilepsy Behav"},{"key":"2021122010153390000_cei12623-bib-0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021122010153390000_cei12623-bib-0041","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.all.0000246619.49494.41","article-title":"Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies","volume":"6","author":"Gardulf","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12623","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.12623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.12623","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/181\/3\/441\/41791720\/cei12623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/181\/3\/441\/41791720\/cei12623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:28:02Z","timestamp":1641054482000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/181\/3\/441\/6422127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,7,7]]},"published-print":{"date-parts":[[2015,8,13]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12623","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,9]]},"published":{"date-parts":[[2015,7,7]]}}}